UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/591,860	09/06/2006	Meiten Koh	Q96559	4402
23373 SUGHRUE MI	7590 09/30/200 ON, PLLC	EXAMINER		
2100 PENNSYLVANIA AVENUE, N.W.			BUIE, NICOLE M	
SUITE 800 WASHINGTON, DC 20037			ART UNIT	PAPER NUMBER
			1796	
			MAIL DATE	DELIVERY MODE
			09/30/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
	10/591,860	KOH ET AL.					
Office Action Summary	Examiner	Art Unit					
	NICOLE M. BUIE	1796					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	Lely filed the mailing date of this communication. (35 U.S.C. § 133).					
Status							
1)⊠ Responsive to communication(s) filed on <u>27 Au</u>	igust 2009						
	action is non-final.						
3) Since this application is in condition for allowan		secution as to the merits is					
closed in accordance with the practice under E							
Disposition of Claims							
4)⊠ Claim(s) <u>1-9,15-17 and 20</u> is/are pending in the	application.						
4a) Of the above claim(s) is/are withdraw	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.	_						
6)⊠ Claim(s) <u>1-9,15-17, and 20</u> is/are rejected.							
7) Claim(s) is/are objected to.							
•							
Application Papers							
9)☐ The specification is objected to by the Examine	•						
	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Ex		, ,					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign	priority under 35 LLS C & 119(a)	-(d) or (f)					
a) ☐ All b) ☐ Some * c) ☐ None of:	priority under 35 0.5.6. § 115(a)	-(u) or (i).					
1. Certified copies of the priority documents	s have been received						
2. Certified copies of the priority documents		on No					
	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.							
Attacker and a							
Attachment(s) 1) X Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)					
Notice of References Cited (P10-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) 🔲 Interview Summary Paper No(s)/Mail Da						
3) Information Disclosure Statement(s) (PTO/SB/08)	5) 🔲 Notice of Informal P						
Paper No(s)/Mail Date	6) [Other:						

Art Unit: 1796

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 08/27/2009 has been entered.

Response to Amendment

The amendment filed 08/27/2009 has been entered. Claims 1-9, 15-17, and 20 remain pending.

The indicated allowability of claims 1-3 and 15 is withdrawn in view of the newly discovered reference(s) to Araki et al. (WO 2002/093249, see US 2005/0004253 A1 for citation). Rejections based on the newly cited reference(s) follow.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-9, 15-17, and 20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Art Unit: 1796

Regarding claims 1-9, 15-17, and 20, the term "ionic liquid type functional material" comprises a compound which may have a charge neutral amino group, while the accepted meaning is "molten salts" as evidenced by the instant specification (See [0005] of the corresponding PG Pub). The term is indefinite because it is unknown how the neutral compound can be an ionic material. For the purpose of this Office Action, "ionic liquid type functional material" will be treated as an aromatic compound which has an amino group and/or salt thereof as required by the claims.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3 and 15 are rejected under 35 U.S.C. 102(b) as being anticipated by Araki et al. (WO 2002/093249 A1, see the English equivalent US 2005/0004253 A1 for citation).

Regarding claims 1-3 and 15, Araki et al. discloses in Preparation Example 10 an allyl ether containing a nonlinear substance in the side chain with the following formula:

Art Unit: 1796

It appears that there was an obvious error in the above structure wherein the second carbon should have one fluorine atom because the above compound is synthesized from the following compound:

Claims 6 and 9 are rejected under 35 U.S.C. 102(b) as being anticipated by Araki et al. (WO 2002/093249 A1, see the English equivalent US 2005/0004253 A1 for citation).

Regarding claims 6 and 9, Araki et al. discloses a fluorine-containing polymer (III) having a moiety exhibiting a nonlinear optical effect in its side chain [0416-0420]. One of the monomers is disclosed in Preparation Example 10 wherein an allyl ether containing a nonlinear substance in the side chain has the following formula:

It appears that there was an obvious error in the above structure wherein the second carbon should have one fluorine atom because the above compound is synthesized from the following compound:

Art Unit: 1796

Response to Arguments

Applicant's arguments have been fully considered and are persuasive. The following comments apply:

A) The previous rejection of claims 6 and 9 under 35 USC 102(b) as being anticipated by Morita is withdrawn in light of Applicants' amendment. Morita et al. does not teach or suggest a structural unit represented by the formula (2-2) with D¹-Ry¹ as recited in the instant claims.

Allowable Subject Matter

Claims 7, 8, and 20 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112, 2nd paragraph, set forth in this Office action.

Claims 4, 5, 16, and 17 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112, 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims.

The following is a statement of reasons for the indication of allowable subject matter: the closest prior art of record, Araki et al. (WO 2002/093249 A1) does not teach or suggest the fluoroether moiety has an amino group and aromatic ring one end and a basic functional and aromatic group on the other end. Araki et al. does not teach or suggest the structural unit M2 of

Art Unit: 1796

instant claim 7 wherein Ry² is an organic group which at least one basic group and contains an aromatic ring and Ra¹ is monovalent organic group.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NICOLE M. BUIE whose telephone number is (571)270-3879. The examiner can normally be reached on Monday-Thursday with alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark Eashoo can be reached on (571)272-1197. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/N. M. B./ Examiner, Art Unit 1796 9/16/2009

/Marc S. Zimmer/

Primary Examiner, Art Unit 1796